STOCK TITAN

Insmed (INSM) Stock News, Oct 2025-Jan 2026

INSM NASDAQ

Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.

Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.

Rhea-AI Summary

Insmed (Nasdaq: INSM) will present four abstracts on treprostinil palmitil inhalation powder (TPIP) at the Pulmonary Vascular Research Institute (PVRI) 2026 congress in Dublin, Jan 28–Feb 1, 2026.

Presentations include the Phase 3 PALM-PAH study design, an encore of topline Phase 2b PAH results, a Functional Respiratory Imaging analysis from Phase 2b, and pulmonary vasodilation data in rat models.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags
none
-
Rhea-AI Summary

Insmed (Nasdaq: INSM) reported preliminary unaudited full-year 2025 net product revenues of $606.4M (up 67% vs. 2024), driven by ARIKAYCE $433.8M and BRINSUPRI $172.7M. BRINSUPRI generated approximately $144.6M in its first full quarter. The company received European approval for BRINSUPRI and plans EU, UK, and Japan launches in 2026. Insmed expects 2026 ARIKAYCE revenue of $450M–$470M, announced key Phase 3 and Phase 2 readout timelines for ENCORE (Mar/Apr 2026) and CEDAR (Q2 2026), initiated PALM-ILD in Q4 2025, and acquired INS1148 in Dec 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
none
-
Rhea-AI Summary

Insmed (Nasdaq: INSM) said management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 3:00 p.m. PT / 6:00 p.m. ET. The presentation will be webcast live and available via the company’s investor relations website. Webcasts will be archived for 30 days after the live event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
none
Rhea-AI Summary

Insmed (Nasdaq: INSM) announced on December 17, 2025 that the Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg arms, and Insmed has discontinued the CRSsNP program effective immediately.

Topline placebo-adjusted least-squares means for 28-day average sTSS at Week 24 were placebo -2.44, brensocatib 10 mg -2.21, and brensocatib 40 mg -2.33. Safety was consistent with prior studies with no new signals. The company also acquired INS1148, a Phase 2–ready monoclonal antibody targeting SCF248, and plans initial development in interstitial lung disease and moderate-to-severe asthma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.08%
Tags
none
-
Rhea-AI Summary

Insmed (Nasdaq: INSM) granted inducement awards to 92 new employees under its 2025 Inducement Plan to meet Nasdaq Listing Rule 5635(c)(4).

On November 28, 2025 the company issued 44,273 restricted stock units and options to purchase an aggregate of 2,490 shares at an exercise price of $207.77 per share (the Nasdaq closing price on the grant date).

The restricted stock units vest over four years with 25% vesting each anniversary of the first day of the month after the grant. Options have a 10-year term and a four-year vesting schedule: 25% at the first anniversary and 12.5% every six months thereafter, subject to continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
Rhea-AI Summary

Insmed (Nasdaq: INSM) announced that the European Commission approved BRINSUPRI (brensocatib) 25 mg on November 18, 2025, as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) in the EU for patients 12+ with ≥2 exacerbations in the prior 12 months.

Approval was granted after EMA accelerated assessment and is supported by Phase 3 ASPEN and Phase 2 WILLOW data showing a 19.4% reduction in annual exacerbation rate and statistically smaller FEV1 decline at week 52. EU access efforts begin in early 2026; U.K. and Japan reviews are ongoing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
none
Rhea-AI Summary

Insmed (Nasdaq: INSM) held its fourth annual Global Day of Good on November 13, 2025, mobilizing more than 1,200 employees across the U.S., Europe, and Japan for simultaneous volunteer activities.

Teams supported health, education, and human services through meal-packing, care packages for children with serious diseases, STEM and hygiene kits, book translation, and outdoor space restoration. The company offers year-round volunteer programs, matching gifts, and paid volunteer time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
none
-
Rhea-AI Summary

Insmed (Nasdaq: INSM) announced management will present at two investor conferences in November and December 2025: the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 8:30 a.m. GT / 3:30 a.m. ET, and the Evercore 8th Annual Healthcare Conference in Coral Gables, Florida on Tuesday, December 2, 2025 at 11:15 a.m. ET.

Both presentations will be webcast live and archived for 30 days on Insmed's investor relations website at www.insmed.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
conferences
-
Rhea-AI Summary

Insmed (Nasdaq: INSM) reported third-quarter 2025 results and a business update on October 30, 2025. Total revenue was $142.3 million in Q3 2025, driven by ARIKAYCE $114.3M (+22% YoY) and BRINSUPRI $28.1M following FDA approval and U.S. launch. The company raised full-year ARIKAYCE guidance to $420M–$430M (15%–18% YoY growth).

R&D and SG&A each were $186.4M in Q3, and Insmed reported a net loss of $370.0M (−$1.75/share). Cash and marketable securities totaled about $1.7B as of Sept 30, 2025. Key clinical catalysts are expected through 2026 across ARIKAYCE, brensocatib, and TPIP programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.33%
Tags
Rhea-AI Summary

Insmed (Nasdaq: INSM) ranked No. 1 on Science's 2025 Top Biopharma Employers list, marking a record fifth consecutive year at the top, announced Oct. 23, 2025. The ranking is based on about 5,500 survey responses, primarily from North America (66%), Europe (20%), and Asia/Pacific Rim (9%). The company linked the recognition to a people-first culture and cited recent clinical successes and regulatory milestones as drivers of growth. Insmed highlighted strengths in corporate image, financial prowess, leadership, work culture, and intellectual challenge. More details and rankings are available on the publisher's feature and Insmed's culture page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none

FAQ

What is the current stock price of Insmed (INSM)?

Insmed (INSM) last closed at $141.33.

What is the market cap of Insmed (INSM)?

The market cap of Insmed (INSM) is approximately $31.0B.